{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T04:29:46Z","timestamp":1769920186397,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T00:00:00Z","timestamp":1468454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T00:00:00Z","timestamp":1468454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Eric Michael Bessell"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of this study is to determine overall survival, disease-specific survival and stoma-free survival after treatment of squamous cell carcinoma of the anus with chemoradiotherapy followed by brachytherapy or electron boost in a recent cohort of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Fifty-two patients (median age 62\u00a0years) were treated with radical chemoradiotherapy (mitomycin C, infusional 5-fluorouracil concurrently with conformal radical radiotherapy 45\u00a0Gy in 25 fractions over 5\u00a0weeks) followed by a radiotherapy boost between 1 December 2000 and 30 April 2011. Follow-up was to 30 November 2014. Thirty-six patients received a boost (15\u201320\u00a0Gy) over 2\u00a0days with <jats:sup>192<\/jats:sup>Ir needle brachytherapy for anal canal tumours, and 16 patients received electron beam therapy (20\u00a0Gy in 10 fractions in 2\u00a0weeks) for anal margin tumours. A defunctioning stoma was only created prior to chemoradiotherapy for fistula or severe anal pain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The overall survival for the 36 patients treated with chemoradiotherapy followed by brachytherapy was 75\u00a0% (95\u00a0% CI, 61\u201389) at 5\u00a0years, the disease-specific survival was 91\u00a0% (95\u00a0% CI, 81\u2013101\u00a0%), and the stoma-free survival was 97\u00a0% (95\u00a0% CI, 91\u2013103\u00a0%) all at 5\u00a0years. For the 16 patients treated with an electron boost for anal margin tumours, the 5-year overall survival, disease-specific survival and stoma-free survival were 68\u00a0% (95\u00a0% CI, 44\u201392\u00a0%), 78\u00a0% (95\u00a0% CI, 56\u2013100\u00a0%) and 80\u00a0% (95\u00a0% CI, 60\u2013100\u00a0%), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A very low stoma formation rate can be obtained with radical chemoradiotherapy followed by a brachytherapy boost for squamous cell carcinoma of the anal canal but not with an electron boost for anal margin tumours.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12029-016-9850-4","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T04:49:07Z","timestamp":1468471747000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chemoradiotherapy with Brachytherapy or Electron Therapy Boost for Locally Advanced Squamous Cell Carcinoma of the Anus\u2014Reducing the Colostomy Rate"],"prefix":"10.1007","volume":"48","author":[{"given":"C.","family":"Kent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. M.","family":"Bessell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. H.","family":"Scholefield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Chappell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Sayers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,14]]},"reference":[{"key":"9850_CR1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.canep.2013.09.015","volume":"37","author":"N Ouhoummane","year":"2013","unstructured":"Ouhoummane N, Steben M, Coutlee F, Vuong T, Forest P, Rodier C, et al. Squamous anal cancer: patients characteristics and HPV type distribution. Cancer Epidemiol. 2013;37:807\u201312.","journal-title":"Cancer Epidemiol"},{"key":"9850_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","volume":"14","author":"RD James","year":"2013","unstructured":"James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous cell carcinoma of the anus (ACT II): a randomised phase 3, open-label. 2\u00a0\u00d7\u00a02 factorial trial. Lancet Oncol. 2013;14:516\u201324.","journal-title":"Lancet Oncol"},{"key":"9850_CR3","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","volume":"299","author":"JA Ajani","year":"2008","unstructured":"Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson III AB, Thomas Jr CR, et al. Fluorouracil, mitomycin and radiotherapy vs fluorouracil, cisplatin and radiotherapy for carcinoma of the anal canal. A randomised controlled trial. JAMA. 2008;299:1914\u201321.","journal-title":"JAMA"},{"key":"9850_CR4","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.radonc.2014.04.013","volume":"111","author":"R Glynne-Jones","year":"2014","unstructured":"Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, et al. Anal cancer: ESMO \u2013 ESSO \u2013 ESTRO clinical practice guidelines for diagnosis, treatment and follow up. Radiother Oncol. 2014;111:330\u20139.","journal-title":"Radiother Oncol"},{"key":"9850_CR5","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","volume":"102","author":"J Northover","year":"2010","unstructured":"Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCR anal cancer trial (ACT I). Br J Cancer. 2010;102:1123\u20138.","journal-title":"Br J Cancer"},{"key":"9850_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/nau.20803","volume":"29","author":"C Norton","year":"2010","unstructured":"Norton C, Whitehead WE, Bliss DZ, Harari D, Long J. Conservative management of faecal incontinence in adults. Committee of the international consultation on incontinence. Management of faecal incontinence in adults. Neurourol Urodyn. 2010;29:199\u2013206.","journal-title":"Neurourol Urodyn"},{"key":"9850_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.clon.2014.03.005","volume":"26","author":"K Spithoff","year":"2014","unstructured":"Spithoff K, Cummings B, Jonker D, Biaggi JJ, on behalf of the gastrointestinal cancer disease site group. Chemoradiotherapy for squamous cell cancer of the anal canal: a systematic review. Clin Oncol (R Coll Radiol). 2014;26:473\u201387.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"9850_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.radonc.2008.05.001","volume":"87","author":"J Widder","year":"2008","unstructured":"Widder J, Kassenberger R, Fercher E, Schmid R, Langendijk JA, Dobrowsky W, et al. Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol. 2008;87:367\u201375.","journal-title":"Radiother Oncol"},{"key":"9850_CR9","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","volume":"30","author":"D Peiffert","year":"2012","unstructured":"Peiffert D, Tournier-Rangeard L, Gerard J-P, Lemanski C, Francois E, Giovannini M, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30:1941\u20138.","journal-title":"J Clin Oncol"},{"key":"9850_CR10","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s00066-014-0628-y","volume":"190","author":"L Lestrade","year":"2014","unstructured":"Lestrade L, De Bari B, Pommier P, Montbarbon X, Lavergne E, Ardiet JM, et al. Role of brachytherapy in the treatment of cancers of the anal canal. Long-term follow-up and multivariate analysis of a large monocentric retrospective series. Strahlenther Onkol. 2014;190:546\u201354.","journal-title":"Strahlenther Onkol"},{"key":"9850_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s13014-014-0240-4","volume":"9","author":"AT Falk","year":"2014","unstructured":"Falk AT, Claren A, Benezery K, Francois E, Gautier M, Gerard J-P, et al. Interstitial high-dose rate brachytherapy as boost for anal canal cancer. Radiat Oncol. 2014;9:240\u20138.","journal-title":"Radiat Oncol"},{"key":"9850_CR12","doi-asserted-by":"crossref","unstructured":"Bazen JG, Hara W, Hsu A, Kunz PA, Ford J, Fisher GA, et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer. 2011;117:3342\u201351.","DOI":"10.1002\/cncr.25901"},{"key":"9850_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","volume":"86","author":"LA Kachnic","year":"2013","unstructured":"Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Wilkins J, Esthappan J, et al. RTOG 0529: a phase II evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86:27\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9850_CR14","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.clon.2014.08.001","volume":"26","author":"R Muirhead","year":"2014","unstructured":"Muirhead R, Adams RA, Gilbert DC, Glynne-Jones R, Harrison M, Sebag-Montefiore D, et al. Anal cancer: developing an intensity modulated radiotherapy solution for ACT 2 fractionation. Clin Oncol (R Coll Radiol). 2014;26:720\u20131.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"9850_CR15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1186\/1471-2407-14-833","volume":"14","author":"A Tozzi","year":"2014","unstructured":"Tozzi A, Cozz L, Iftode C, Ascolese A, Campisi MC, Clerici E, et al. Radiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapy. BMC Cancer. 2014;14:833\u201342.","journal-title":"BMC Cancer"},{"key":"9850_CR16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1748-717X-7-45","volume":"7","author":"S Vieillot","year":"2012","unstructured":"Vieillot S, Fenoglietto P, Lemanski C, Moscardo CL, Gourgou S, Dubois J-B, et al. IMRT for locally advanced anal cancer: clinical experience of the Montpellier cancer center. Radiat Oncol. 2012;7:45\u201352.","journal-title":"Radiat Oncol"},{"key":"9850_CR17","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.ijrobp.2014.02.012","volume":"89","author":"JC Hodges","year":"2014","unstructured":"Hodges JC, Beg MS, Das P, Meyer J. Cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for anal cancer. Int J Radiat Oncol Biol Phys. 2014;89:773\u201383.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9850_CR18","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","volume":"14","author":"M Flam","year":"1996","unstructured":"Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy and of salvage chemoradiation in the definitive non-surgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527\u201339.","journal-title":"J Clin Oncol"},{"key":"9850_CR19","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"H Bartelink","year":"1997","unstructured":"Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol. 1997;15:2040\u20139.","journal-title":"J Clin Oncol"},{"key":"9850_CR20","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1200\/JCO.2008.19.6857","volume":"27","author":"JA Ajani","year":"2009","unstructured":"Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr., et al. US intergroup anal carcinoma trial: tumour diameter predicts for colostomy. J Clin Oncol. 2009;27:1116\u201321.","journal-title":"J Clin Oncol"},{"key":"9850_CR21","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1200\/JCO.2009.22.8890","volume":"27","author":"K Vordermark","year":"2009","unstructured":"Vordermark K. Cause-specific colostomy rates after chemoradiotherapy for anal carcinoma: cancer-related versus treatment-related colostomy. J Clin Oncol. 2009;27:3064.","journal-title":"J Clin Oncol"},{"key":"9850_CR22","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1200\/JCO.2011.36.1790","volume":"29","author":"KG Sunesen","year":"2011","unstructured":"Sunesen KG, Norgaard M, Lundby L, Harsteen H, Buntzen S, Thorlacius-Ussing O, et al. Cause-specific colostomy rates after radiotherapy for anal cancer: a Danish multicentre cohort study. J Clin Oncol. 2011;29:3535\u201340.","journal-title":"J Clin Oncol"},{"key":"9850_CR23","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ijrobp.2013.07.035","volume":"87","author":"LL Gunderson","year":"2013","unstructured":"Gunderson LL, Monghan J, Ajani JA, Pederson JE, Winter KA, Benson AB III, et al. Anal carcinoma: impact of TN category of disease on survival, disease relapse and colostomy failure in US gastrointestinal group RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013;87:638\u201345.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9850_CR24","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/annonc\/mdu188","volume":"25","author":"R Glynne-Jones","year":"2014","unstructured":"Glynne-Jones R, Kadalayi L, Meadows HM, Cunningham D, Samuel L, Geh J, ACT II Study Group, et al. Tumour \u2013 and treatment-related colostomy rates following mitomycin-C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial. Ann Oncol. 2014;25:1616\u201322.","journal-title":"Ann Oncol"},{"key":"9850_CR25","doi-asserted-by":"crossref","unstructured":"Brown SR, Wadhawan H, Nelson RL. Surgery for faecal incontinence in adults. Cochrane Database Syst Rev. 2013.","DOI":"10.1002\/14651858.CD001757.pub4"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-016-9850-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-016-9850-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-016-9850-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-016-9850-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:31:56Z","timestamp":1628598716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-016-9850-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,14]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["9850"],"URL":"https:\/\/doi.org\/10.1007\/s12029-016-9850-4","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,14]]},"assertion":[{"value":"14 July 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients gave informed written consent to treatment. The project was considered by the Nottingham Research Ethics Committee as an audit and hence was ethically approved as part of a cohort of audits undertaken at the time by Nottingham University Hospital NHS Trust. An individual ethical assessment of this project was not deemed necessary. In addition, ethical approval was obtained from Trent Cancer Registry to access data on patients with anal cancer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}